Company
Saniona AB
Headquarters: Glostrup, Denmark
Employees: 53
CEO: Mr. Rami Levin
Market Cap
€18.2 Million
EUR as of Jan. 1, 2023
US$19.4 Million
Saniona AB Categories
Denmark
languages
Healthcare
languages
Biotechnology
Denmark Healthcare
Denmark Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
|
Novo Nordisk
|
$304.61 B |
CSL Limited
|
$93.24 B |
Regeneron Pharmaceuticals, Inc.
|
$79.53 B |
| Marinomed Biotech AG | $76.72 B |
|
Vertex Pharmaceuticals Incorporated
|
$74.13 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$495.37 B |
|
Johnson & Johnson
|
$461.85 B |
|
Lilly
|
$347.61 B |
|
Novo Nordisk
|
$304.61 B |
|
Pfizer
|
$287.63 B |
Detailed Description
Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. The company's products include Tesofensine, a triple monoamine reuptake inhibitor; Tesomet, a fix-dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; and CAD-1883 for movement disorders. It is also developing SAN711 for rare neuropathic disorders, which is in Phase 1; SAN903 that is in preclinical stage for rare inflammatory/fibrotic disorders; and Boehringer Ingelheim program for schizophrenia. In addition, it has a portfolio of various drug candidates in pre-clinical and clinical stages. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Stocks & Indices
Saniona AB has the following listings and related stock indices.
Stock: FSX: 30S
Stock: OMX: SANION